Placebo Surgery for Parkinson's Disease: Do the Benefits Outweigh the Risks?

• DOI: 10.1111/j.1748-720x.2002.tb00720.x
• Publication Date: 2007-01-25T10:36:13Z
• Authors: Peter A. Clark
• Keywords: Male; Informed Consent; Patient Selection; Beneficence; Parkinson Disease; 06 humanities and the arts; Placebo Effect; 0603 philosophy, ethics and religion; Control Groups; Risk Assessment; Neurosurgical Procedures; Nontherapeutic Human Experimentation; 3. Good health; Personhood; Placebos; Substantia Nigra; Fetal Tissue Transplantation; Social Justice; Humans; Ethics, Medical; Female; Patient Participation; Randomized Controlled Trials as Topic

In April 1999, Dr. Curt Freed of the University of Colorado in Denver and Dr. Stanley Fahn of Columbia Presbyterian Center in New York presented the results of a four-year, $5.7 million government-financed study using tissue from aborted fetuses to treat Parkinson’s disease at a conference of the American Academy of Neurology. The results of the first government-financed, placebo-controlled clinical study using fetal tissue showed that the symptoms of some Parkinson’s patients had been relieved. This research study involved forty subjects, nineteen women and twenty-one men; all suffered from Parkinson’s disease for an average of 13.5 years. In the study, each subject underwent neurosurgery: “four tiny burr holes, drilled through the wrinkle lines above the eyebrows into the skull, to clear a pathway to the brain. But only half received injections of fetal cells into the putamen, the region of the brain that controls movement; the other half received nothing. One year later, three members of the placebo group said their symptoms had improved.” In two-thirds of the transplant recipients, the fetal tissue took hold and seemed to establish a new network to produce the missing neurochemical dopamine.